High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)

Blood

Volumn 117, Issue 3, 2011, Pages 928-935

  Kuipers, Jenny E ^a   Coenen, Eva A ^a   Balgobind, Brian V ^a   Stary, Jan ^b   Baruchel, Andre ^c   De Haas, Valerie ^d   De Bont, Eveline S J M ^e   Reinhardt, Dirk ^f   Kaspers, Gertjan J L ^g   Cloos, Jacqueline ^g   Danen van Oorschot, Astrid A ^a   Den Boer, Monique L ^a   Marschalek, Rolf ^h   Meyer, Claus ^h   Pieters, Rob ^a   Zwaan, C Michel ^a   Van Den Heuvel Eibrink, Marry M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b CHARLES UNIVERSITY   (Czech Republic)

^c SAINT LOUIS HOSPITAL   (France)

^d DCOG Dutch Childhood Oncology Group   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f AML BFM Study Group   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL ADHESION MOLECULE; PROTEIN IGSF4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METHYLATION; NEWBORN; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 78751692203     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-286138     Document Type: Article

References (31)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
2. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94(11):3707-3716.
3. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109(11):4641-4647. (Pubitemid 46827753)
4. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519-1532.
5. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Pediatr Clin North Am. 2008;55(1):21-51, ix.
6. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490-1499.
7. Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHOAML trials. Br J Haematol. 2003;122(2):217-225.
8. Palle J, Frost BM, Forestier E, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol. 2005;129(2):189-198.
9. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20(9):2302-2309. (Pubitemid 34441657)
10. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
11. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21(17):3262-3268.
12. Kaspers GJ, Veerman AJ, Pieters R, et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer. 1994;70(6):1047-1052. (Pubitemid 24358937)
13. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10):3520-3529.
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307-315. (Pubitemid 38262761)
15. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002;18(suppl 1):S96-S104.
16. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3. http://www.statsci.org/smyth/pubs/ebayes.pdf. Accessed May 25, 2010.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B. 1995;57(1):289-300.
18. Tissing WJ, Meijerink JP, Brinkhof B, et al. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood. 2006;108(3):1045-1049. (Pubitemid 44154643)
19. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C - metabolizing enzymes explains Ara-C sensitivity in MLL generearranged infant acute lymphoblastic leukemia. Blood. 2003;101(4):1270-1276.
20. Overmeer RM, Henken FE, Snijders PJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008;215(4):388-397.
21. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76(11):2327-2336.
22. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human nonsmall-cell lung cancer. Nat Genet. 2001;27(4):427-430.
23. Masuda M, Yageta M, Fukuhara H, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem. 2002;277(34):31014-31019. (Pubitemid 34970805)
24. Michels E, Hoebeeck J, De Preter K, et al. CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer. 2008;8:173.
25. Entrez gene CADM1 Homo Sapiens. http://www.ncbi.nlm.nih.gov/gene/23705. Accessed May 25, 2010.
26. Boles KS, Barchet W, Diacovo T, Cella M, Colonna M. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood. 2005;106(3):779-786. (Pubitemid 41076415)
27. Kawano S, Ikeda W, Kishimoto M, Ogita H, Takai Y. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. J Biol Chem. 2009;284(35):23793-23805.
28. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009;113(26):6558-6566.
29. Hollink IH, van den Heuvel-Eibrink MM, Zwaan CM. CEBPA resembles Roman god Janus. Blood. 2009;113(26):6501-6502.
30. Röhrs S, Dirks WG, Meyer C, et al. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer. 2009;8:86.
31. Dewan MZ, Takamatsu N, Hidaka T, et al. Critical role for TSLC1 expression in the growth and organ infiltration of adult T-cell leukemia cells in vivo. J Virol. 2008;82(23):11958-11963.